RN7SL309P

Across TCGA pan-cancer cohorts, RN7SL309P RNA is linked to patient survival in 12 of 34 cancer types, making it the most broadly survival-associated RN7SL309P data layer.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where higher RN7SL309P RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RN7SL309P expression acts as an unfavorable survival marker, although some lineages such as OV show a favorable association.

LIHC, OV, and BRCA are the cancer types where RN7SL309P RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LIHC	DFS	Tertile	All	0.087	0.555	<.001	108	view →
OV	DFS	Tertile	All	0.515	0.365	.021	48	view →
BRCA	DFS	Tertile	All	0.140	1.000	.001	36	view →
UCEC	DFS	Tertile	III,IV	0.538	0.809	.012	36	view →
KIRC	OS	Tertile	All	0.428	0.652	<.001	24	view →
SARC	DFS	Tertile	All	0.043	0.596	<.001	18	view →
LUAD	OS	Tertile	IV	0.153	0.714	.012	18	view →
MESO	DFS	Tertile	III,IV	0.168	0.418	.041	9	view →
STAD	DFS	Tertile	IV	0.083	0.379	.001	9	view →
SKCM	OS	Tertile	III,IV	0.175	0.698	.004	9	view →
THCA	DFS	Tertile	II,III,IV	0.133	0.764	.048	9	view →
LUSC	DFS	Tertile	All	0.306	0.648	.029	9	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 12 lineages.

RN7SL309P–LIHC (DFS)

Open the LIHC breakdown →